ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025
Exploration of the mechanism of Danggui Buxue decoction for the treatment of gastric ulcer based on network pharmacology, molecular docking, and experiment.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Validating the potential mechanism and therapeutic effect of Qinlian Jiangxia decoction in the treatment of type 2 diabetes mellitus complicated with hyperlipidemia through network pharmacology, molecular docking, molecular dynamics simulation, andexperiments.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo explore the mechanism of Danggui Buxue decoction (, DBD) for the treatment of gastric ulcer (GU), based on network pharmacology and
methodsA network pharmacology strategy was used to predict the main components, candidate targets, and potential signaling pathways. Then, molecular docking was performed to further investigate the interactions and binding affinities between the main components and primary targets. Finally, a mouse model of ethanol-induced gastric ulcers was established to confirm the efficacy and potential therapeutic benefits of DBD, and candidate targets were finally identified.
resultsA total of 22 active components and 220 target genes were found to be associated with DBD. In addition, 343 GU-related target genes and 57 target genes specific to DBD treatment of GU were identified. The Gene Ontology functional enrichment analysis revealed 510 entries for biological processes, 36 entries for cell composition, and 69 entries for molecular functions. In the pathway enrichment analysis, 143 signaling pathways were identified. Additionally, the molecular docking results revealed that the main active components of DBD exhibited a strong binding capacity with key proteins, including tumor necrosis factor, AKT serine/threonine kinase 1, interleukin-6, vascular endothelial growth factor, and interleukin-1 Beta. Among these, quercetin, kaempferol, formononetin, isorhamnetin, and beta-sitosterol displayed the strongest binding affinities for these key proteins.
conclusionsBased on network pharmacology analysis and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.